Ipamorelin: The Selective Growth Hormone Secretagogue — Complete Research Profile

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) designed to selectively stimulate growth hormone (GH) release from the anterior pituitary gland. With the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, it has a molecular weight of approximately 711.85 Da and represents one of the most precisely engineered growth hormone-releasing peptides (GHRPs) in the research literature.

For dosing, reconstitution, and protocol details, see our Ipamorelin Dosage Protocol Guide 2026: Reconstitution, Timing & Research Use.

First described in a landmark 1998 study by Raun and colleagues published in the European Journal of Endocrinology, ipamorelin was characterized as the first GHRP-receptor agonist to demonstrate a selectivity for GH release comparable to that of growth hormone-releasing hormone (GHRH) itself — stimulating robust GH output while leaving cortisol, ACTH, and prolactin levels essentially unchanged. This selectivity profile marked a significant departure from earlier GHRPs and established ipamorelin as a reference compound for understanding the pharmacology of the GHS-R1a receptor system.

In research contexts, ipamorelin's combination of potent GH release, clean hormonal profile, predictable dose-response kinetics, and short half-life makes it a versatile tool for investigating GH pulsatility, somatotroph function, and the downstream effects of GH/IGF-1 signaling on tissues including bone, muscle, and adipose tissue.

---

Molecular Structure and Chemical Properties

Ipamorelin's structure was rationally designed to optimize binding at the ghrelin receptor (GHS-R1a) while minimizing interaction with receptors responsible for ACTH and cortisol release. Several structural features define its pharmacological behavior:

Pentapeptide backbone: Five amino acid residues connected in the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, where Aib (alpha-aminoisobutyric acid) is a non-natural amino acid that confers metabolic stability against proteolytic enzymes compared to conventional L-amino acid sequences.

D-amino acid substitutions: D-2-Nal (D-2-naphthylalanine) and D-Phe (D-phenylalanine) at positions 3 and 4 provide conformational rigidity and resistance to enzymatic degradation, extending the plasma half-life relative to endogenous ghrelin.

C-terminal amidation: The NH₂ amide group at the C-terminus is a common structural feature in many biologically active peptides; it protects against carboxypeptidase activity and contributes to receptor binding affinity.

Molecular formula: C₃₈H₄₉N₉O₅ with a molecular weight of 711.85 Da.

CAS Number: 170851-70-4

These structural features collectively produce a molecule with sufficient receptor affinity to produce maximal or near-maximal GH release at low nanomolar concentrations, while the selectivity built into the scaffold ensures minimal off-target receptor engagement at the ACTH/cortisol axis.

---

Mechanism of Action

The Ghrelin Receptor: GHS-R1a

Ipamorelin's primary target is the growth hormone secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor. GHS-R1a is a G protein-coupled receptor (GPCR) expressed predominantly on somatotroph cells of the anterior pituitary gland, as well as in the hypothalamus, hippocampus, and other peripheral tissues.

When ipamorelin binds to GHS-R1a on pituitary somatotrophs, it activates the Gq/11 signaling pathway, triggering phospholipase C (PLC) activation, inositol trisphosphate (IP₃) generation, and subsequent calcium release from intracellular stores. This calcium mobilization leads directly to exocytosis of stored GH granules. Concurrently, GHS-R1a signaling also activates adenylyl cyclase via Gs coupling, increasing intracellular cAMP and providing a secondary signal amplification mechanism.

Dual-Axis GH Release

Understanding ipamorelin's mechanism requires appreciating that GH secretion from the pituitary is governed by two competing hypothalamic signals:

GHRH pathway (stimulatory): Growth hormone-releasing hormone (GHRH) released from the arcuate nucleus of the hypothalamus binds the GHRH receptor on somatotrophs, activating Gs/adenylyl cyclase/cAMP signaling to stimulate GH release.

Somatostatin pathway (inhibitory): Somatostatin (SRIF, somatotropin release-inhibiting factor) released from periventricular neurons acts as a brake on GH secretion, maintaining the pulsatile pattern of GH release by periodically suppressing somatotroph activity.

Ipamorelin, like all GHRPs and ghrelin itself, stimulates GH release through two complementary mechanisms: (1) directly activating GHS-R1a on somatotrophs via the Gq/Gs pathway, and (2) acting at the level of the hypothalamus to suppress somatostatin release, thereby disinhibiting the pituitary's response to GHRH. This dual action at both pituitary and hypothalamic levels explains why ipamorelin's GH-releasing effect is synergistic when combined with GHRH analogs — the two peptide classes enhance GH output through mechanistically distinct but complementary pathways.

Preserving Physiological Pulse Patterns

A critical feature of ipamorelin's mechanism is that it amplifies existing GH pulses rather than overriding them. Because ipamorelin's effect is partially mediated by somatostatin suppression and partly by direct GHS-R1a activation, GH release occurs preferentially during the troughs in somatostatin activity — times when the pituitary is primed to respond. This means that ipamorelin administration tends to reinforce natural GH pulsatility rather than producing a sustained, non-pulsatile elevation, which is considered more physiologically appropriate and avoids some of the receptor downregulation seen with continuous GH infusion.

GH-Mediated Downstream Signaling

Once released, GH acts on peripheral tissues through several mechanisms. In the liver, GH binds to the GH receptor and stimulates synthesis and secretion of insulin-like growth factor-1 (IGF-1), the primary anabolic mediator of GH's effects on muscle, bone, and other tissues. IGF-1 acts both in an endocrine manner (circulating systemically) and in autocrine/paracrine fashions within local tissues.

GH also exerts direct effects independent of IGF-1: stimulating lipolysis in adipose tissue, opposing some insulin actions (particularly glucose uptake in peripheral tissues), and influencing protein synthesis in muscle and liver. The relative contributions of direct GH effects versus IGF-1-mediated effects depend on the tissue, the duration of GH stimulation, and the ambient hormonal environment.

---

The Selectivity Advantage: Ipamorelin vs. Earlier GHRPs

The Problem with Earlier Growth Hormone Secretagogues

To fully appreciate ipamorelin's significance, it helps to understand the limitations of earlier GHRPs. GHRP-6, for example, was one of the first peptidyl GH secretagogues studied extensively. While potent in stimulating GH release, GHRP-6 produced a range of off-target effects that complicated research protocols and limited clinical utility:

• •Significant cortisol/ACTH elevation: GHRP-6 robustly stimulates the hypothalamic-pituitary-adrenal (HPA) axis, elevating ACTH and cortisol in a dose-dependent manner. In research settings, this cortisol elevation confounds studies of body composition, metabolic function, and stress responses.
• •Prolactin increase: GHRP-6 elevates prolactin, which complicates studies in subjects where prolactin activity is a variable of interest and raises concerns about longer-term protocol design.
• •Pronounced appetite stimulation: GHRP-6 strongly activates ghrelin-mediated appetite pathways, producing significant hunger — an effect mediated through ghrelin receptor activation in the hypothalamus and vagal afferents. This orexigenic effect can complicate controlled dietary research and is undesirable in many clinical applications.
• •Potential for desensitization: Continuous or high-dose GHRP-6 administration may lead to GHS-R1a desensitization through receptor internalization and downregulation.

Ipamorelin's Selective Profile

The Raun et al. 1998 study established definitively that ipamorelin released ACTH and cortisol at levels not significantly different from those seen following GHRH administration — even at concentrations more than 200-fold higher than the ED50 for GH release. This ratio of selectivity is remarkable and forms the cornerstone of ipamorelin's value in research.

Why does ipamorelin spare the cortisol axis? The precise molecular basis involves the specific receptor conformations that ipamorelin stabilizes upon binding GHS-R1a. Ipamorelin appears to act as a "biased agonist" — stabilizing receptor conformations that preferentially couple to GH-releasing pathways while failing to activate (or weakly activating) the intracellular signaling cascades that lead to ACTH/cortisol release. This biased agonism at the level of GHS-R1a represents a significant pharmacological advance over earlier GHRP structures.

No meaningful appetite stimulation: Unlike GHRP-6, ipamorelin does not produce clinically significant appetite stimulation at research doses. This reflects subtle differences in how ipamorelin interacts with GHS-R1a in the hypothalamic circuits governing feeding behavior versus pituitary GH release circuits.

Minimal prolactin effect: Ipamorelin's prolactin-sparing profile makes it preferable to GHRP-6 and GHRP-2 in protocols where hyperprolactinemia could confound results or create side effects.

Why Selectivity Matters in Research

The practical importance of ipamorelin's selectivity extends beyond academic interest. When studying the effects of elevated GH and IGF-1 on outcomes like body composition, bone metabolism, sleep quality, or cognitive function, confounding elevations in cortisol introduce a major experimental variable. Cortisol is catabolic (opposed to the anabolic GH signal), promotes adipogenesis, affects sleep architecture, suppresses immune function, and influences bone turnover — all outcomes that researchers often examine in GH peptide studies. By using ipamorelin rather than GHRP-6, investigators can attribute observed outcomes more confidently to the GH/IGF-1 axis rather than to concurrent HPA axis activation.

---

Pharmacokinetics and GH Release Dynamics

Half-Life and Plasma Clearance

Ipamorelin exhibits a short terminal half-life of approximately 2 hours following subcutaneous administration. The key pharmacokinetic parameters established in human volunteer studies include:

• •Terminal half-life (t½): ~2 hours
• •Clearance: ~0.078 L/h/kg
• •Volume of distribution at steady state (Vdss): ~0.22 L/kg
• •Dose-proportional pharmacokinetics: Plasma concentrations scale linearly with dose across the studied range

These parameters indicate that ipamorelin distributes primarily in extracellular fluid rather than accumulating significantly in tissues, consistent with its profile as a hydrophilic peptide that does not bind appreciably to plasma proteins. The relatively small volume of distribution also implies limited peripheral tissue sequestration.

GH Pulse Profile Following Administration

The GH release profile following ipamorelin injection is characteristically sharp and pulsatile:

• •Time to peak GH (Tmax): Approximately 0.67 hours (~40 minutes) post-injection in pharmacokinetic/pharmacodynamic modeling studies
• •Pulse duration: GH concentrations decline exponentially from peak, returning to near-baseline levels within 3-4 hours
• •Peak GH amplitude: Dose-dependent, with maximal GH production rates modeled at approximately 694 mIU/L/hour in human PK/PD studies

This sharp, defined pulse pattern is physiologically relevant — natural GH secretion occurs as discrete pulses, primarily during sleep, rather than as sustained continuous secretion. Ipamorelin's pharmacodynamic profile closely mimics this pattern, supporting its use in research investigating physiological GH pulsatility.

Dose-Response Characteristics

Ipamorelin exhibits a well-defined dose-response relationship for GH release:

• •The EC50 (concentration required for half-maximal GH stimulation) is approximately 214 nmol/L in pharmacodynamic models
• •GH response increases with dose up to a ceiling effect at higher concentrations
• •The dose-response curve is steep in the clinically relevant range (100-300 mcg), meaning precise dose selection is important for controlling GH pulse amplitude in research protocols

---

Research Evidence: Key Study Areas

Foundational Selectivity Research

The pivotal Raun et al. (1998) study in conscious swine remains the reference publication for ipamorelin's selectivity profile. Key findings included:

• •Ipamorelin released GH with an ED50 of 2.3 ± 0.03 nmol/kg and an Emax of 65 ± 0.2 ng GH/mL plasma — comparable to GHRP-6
• •No significant release of ACTH, cortisol, or prolactin at doses up to 200× the GH-releasing ED50
• •The GH-releasing potency of ipamorelin from primary rat pituitary cells was similar to GHRP-6, confirming equivalent direct pituitary activity
• •In vivo, ipamorelin produced more selective GH stimulation than any previously characterized GHRP compound

GH Pulsatility Studies

The pharmacokinetic-pharmacodynamic (PK/PD) study by Raun and colleagues (European Journal of Pharmaceutical Sciences, 1999) characterized ipamorelin's GH dynamics in healthy human volunteers. Using population PK/PD modeling approaches, the study established:

• •A direct-link PK/PD model adequately described the GH response following single subcutaneous doses
• •GH release followed an indirect response model, with ipamorelin stimulating GH production rate in a concentration-dependent manner
• •Dose-proportional GH exposure was confirmed across the studied dose range
• •Subcutaneous bioavailability was sufficient to produce significant GH responses

These findings established the quantitative framework for understanding how ipamorelin dosing translates to GH exposure and downstream IGF-1 effects.

Bone Density and Longitudinal Bone Growth

A 1999 study by Svensson and colleagues (Endocrinology) examined ipamorelin's effects on bone growth in animal models. The research demonstrated that ipamorelin:

• •Significantly increased longitudinal bone growth rate in a dose-dependent manner in rats
• •Produced bone growth effects comparable to those of GH and IGF-1 at equivalent doses
• •Reversed glucocorticoid-induced suppression of bone growth — a relevant finding given that corticosteroid-induced bone loss (osteoporosis) is a significant clinical problem
• •Enhanced bone mineral content in female rats treated over extended periods

The mechanism underlying ipamorelin's bone effects involves GH-stimulated production of systemic IGF-1 combined with local paracrine IGF-1 action in growth plate chondrocytes and osteoblasts. GH and IGF-1 promote chondrocyte proliferation in the growth plate, stimulate collagen synthesis in osteoblasts, and enhance calcium absorption from the gut — collectively driving net bone formation.

For research applications, the bone growth data positions ipamorelin as a valuable tool for studying the GH/IGF-1 axis in models of glucocorticoid-induced osteoporosis, growth disorders, and age-related bone loss.

Body Composition Research

The effects of ipamorelin-induced GH elevation on body composition have been examined in both animal and preliminary human studies. The primary mechanisms driving body composition effects include:

Lipolysis stimulation: GH directly activates adipocyte lipolysis by increasing hormone-sensitive lipase (HSL) activity, promoting release of free fatty acids from triglyceride stores. This lipolytic effect is most pronounced in visceral adipose tissue, which expresses high levels of GH receptors.

Anabolic effects on lean mass: IGF-1, produced in response to GH stimulation, acts on muscle satellite cells to promote myoblast proliferation and differentiation, contributing to muscle hypertrophy and lean mass preservation. IGF-1 also stimulates protein synthesis in existing muscle fibers through Akt/mTOR signaling pathways.

Metabolic rate effects: GH has complex interactions with intermediary metabolism. Acutely, GH has insulin-antagonistic effects; chronically, optimized GH levels support metabolic rate and thermogenic capacity in brown adipose tissue.

Research protocols using ipamorelin have demonstrated improvements in body composition parameters including reduced fat mass and preserved or increased lean mass, though the magnitude of these effects is highly dependent on dosing frequency, duration, and concurrent dietary and exercise conditions.

IGF-1 and Anabolic Axis

Ipamorelin's value as a research tool for the somatotropic axis includes its ability to investigate IGF-1 biology. Unlike exogenous GH or IGF-1 administration, ipamorelin stimulates the entire physiological signaling cascade — pituitary GH release leads to hepatic IGF-1 synthesis, with feedback regulation intact. This means that:

• •IGF-1 levels remain under normal feedback control, with less risk of supraphysiological elevation
• •The ratio of GH to IGF-1 remains within physiological ranges
• •Both endocrine (liver-derived) and autocrine/paracrine (local tissue) IGF-1 production are stimulated, as occurs in normal physiology

This preservation of the full GH/IGF-1 axis (rather than bypassing it with exogenous IGF-1) makes ipamorelin an appropriate model compound for studying the integrated somatotropic axis in preclinical and early clinical research.

---

Ipamorelin vs. GHRP-6: A Detailed Comparison

Understanding how ipamorelin compares to GHRP-6 — the prototype peptidyl GH secretagogue — clarifies its unique position in peptide research.

GH-Releasing Potency

Both ipamorelin and GHRP-6 activate GHS-R1a and release GH with comparable potency in primary pituitary cell assays. In vivo, ipamorelin's ED50 for GH release (~2.3 nmol/kg in swine) is similar to GHRP-6, and maximal GH responses are equivalent between the two compounds in controlled conditions. Where they differ is not in GH potency but in selectivity.

Cortisol and ACTH

• •GHRP-6: Produces significant, dose-dependent ACTH and cortisol elevation. In human studies, GHRP-6 administration at typical research doses elevates cortisol by 20-50% above baseline. This HPA activation is consistent across species and represents a fundamental limitation for research protocols requiring clean GH stimulation.
• •Ipamorelin: Produces ACTH and cortisol elevations that are not statistically different from those induced by GHRH administration (minimal to none) at doses up to 200× the GH-releasing ED50. This selectivity is robust and reproducible across species studied.

Prolactin

• •GHRP-6: Elevates prolactin levels in a dose-dependent manner, a potential confounder in research examining reproductive physiology, sexual function, or mood.
• •Ipamorelin: Does not produce meaningful prolactin elevation at research doses.

Appetite and Orexigenic Effects

• •GHRP-6: Strongly stimulates appetite through ghrelin-mimetic activation of hypothalamic hunger circuits. This orexigenic effect is significant in controlled dietary studies and may be problematic in long-duration protocols.
• •Ipamorelin: Does not produce clinically significant appetite stimulation at standard research doses. This difference is attributed to differential engagement of GHS-R1a conformations in hypothalamic versus pituitary circuits.

Research Implication Summary

For research protocols requiring clean GH stimulation without HPA axis confounds, ipamorelin's superiority over GHRP-6 is well-established in the literature.

---

Synergy with CJC-1295: The Dual-Axis Approach

Mechanistic Rationale for Combination

One of the most replicated observations in GH peptide research is that GHRPs and GHRH analogs act synergistically when administered together. The mechanistic basis lies in their complementary receptor targets:

• •GHRH analogs (CJC-1295, sermorelin) act via the GHRH receptor (GHRH-R), increasing intracellular cAMP in somatotrophs and stimulating GH synthesis and secretion. CJC-1295, a modified GHRH analog with extended half-life, provides sustained GHRH-R stimulation.
• •GHRPs (ipamorelin) act via GHS-R1a, stimulating GH release through calcium mobilization and also suppressing somatostatin release from the hypothalamus.

When both pathways are activated simultaneously:

1. CJC-1295 fills the GHRH-R, maximizing adenylyl cyclase activation

2. Ipamorelin fills GHS-R1a, providing the calcium signal

3. Ipamorelin's hypothalamic action suppresses somatostatin, removing the main brake on GH release

4. The result: a GH pulse that is 2-4× larger than either compound alone can produce

Research published in peer-reviewed literature confirmed this synergy: co-administration of GHRH-analog with ipamorelin produced co-administration GH AUC values significantly exceeding the sum of individual compounds' effects.

CJC-1295 Pharmacokinetics and the Research Implications

CJC-1295 (without DAC) has a half-life of approximately 30 minutes, making its peak action relatively coincident with ipamorelin's 40-minute GH peak. CJC-1295 with DAC (Drug Affinity Complex) achieves a much longer half-life (6-8 days) by covalently binding to albumin via a reactive ester moiety, creating a long-acting GHRH analog that produces sustained GH/IGF-1 elevation over days.

The research implications of the CJC-1295/ipamorelin combination extend to:

• •Optimized GH pulse amplitude at each injection
• •Potential for sustained IGF-1 elevation with the DAC formulation
• •Complementary mechanistic coverage of the full GH-releasing pathway
• •Reduced tachyphylaxis compared to high-dose single-agent protocols, as each receptor system is stimulated at lower occupancy

For detailed mechanistic comparison, see the CJC-1295 vs Ipamorelin comparison article and the Growth Hormone Secretagogues Compared resource.

---

Research Dosing Protocols

Standard Dosing Parameters

Research protocols examining ipamorelin typically employ the following parameters, derived from PK/PD modeling and empirical dose-finding studies:

Dose range: 100–300 mcg per injection (subcutaneous administration)

• •100 mcg: Lower-dose protocols; useful for studying baseline GH responsiveness or in combination with potent GHRH analogs where GH amplification is already achieved through the GHRH pathway
• •200 mcg: Moderate dose commonly used in body composition and IGF-1 research
• •300 mcg: Near-maximal GH-releasing dose for most subjects in acute GH response studies

Administration frequency:

• •Once daily (QD): Single nocturnal injection 30-60 minutes before sleep, exploiting the natural nighttime GH surge and avoiding interference with food-stimulated insulin secretion
• •Two times daily (BID): Injections timed to replicate two of the natural GH pulse windows (e.g., morning fasted + pre-sleep)
• •Three times daily (TID): Higher-frequency protocols for sustained IGF-1 elevation research; typically administered fasted to maximize GH response (food, particularly carbohydrates and fats, transiently suppresses GH release by increasing somatostatin tone)

Timing optimization:

Because GH release is suppressed by elevated blood glucose (via increased somatostatin), ipamorelin is typically administered during fasting periods for maximum response. Research protocols often specify:

• •Pre-sleep administration (fasted, 2-3 hours post-last meal)
• •Pre-training in exercise studies (fasted or 2+ hours post-meal)
• •Morning fasting administration for AM GH pulse studies

Cycle duration in research:

Research protocols examining body composition typically run 8-12 week observation periods, with washout periods of 4+ weeks to allow normalization of GH/IGF-1 axis feedback. Longer-duration studies (up to 12 months) have been conducted for bone density outcomes, given the slower turnover rate of bone compared to soft tissue.

Combination Protocol Design

When studying ipamorelin in combination with CJC-1295, timing considerations include:

• •Co-administration: Injecting both simultaneously exploits the synergistic GH release at the time of peak somatotroph responsiveness
• •Sequential administration: Some protocols inject CJC-1295 (without DAC) 5-10 minutes before ipamorelin to prime GHRH-R activation before adding the GHS-R1a signal
• •Separate injection sites: To avoid potential peptide-peptide interactions in solution, separate subcutaneous injection sites are recommended when using two peptides

See the peptide half-life reference guide for detailed pharmacokinetic comparisons across GH peptides relevant to research protocol design.

---

Safety Profile and Research Considerations

Observed Safety Parameters

Within the documented research literature, ipamorelin demonstrates a favorable acute safety profile:

Glucocorticoid/HPA axis: Unlike GHRP-6 and GHRP-2, ipamorelin does not meaningfully activate the HPA axis. This has practical implications for research: long-term cortisol elevation is associated with metabolic syndrome, impaired immunity, sleep disruption, and catabolic effects on muscle and bone — all outcomes that would confound GH research endpoints.

Prolactin: Prolactin-sparing profile reduces concerns about galactorrhea, sexual dysfunction, or mood effects that have been associated with prolactin elevation in GHRP-2 research protocols.

Appetite/orexigenic effects: Minimal appetite stimulation preserves dietary control in research settings and makes ipamorelin suitable for studies where food intake is a controlled variable.

Water retention: GH-mediated sodium and water retention is a recognized effect of pharmacological GH elevation. Ipamorelin, by stimulating physiological GH pulses rather than producing sustained supraphysiological GH levels, typically produces less pronounced fluid retention than exogenous GH at equivalent doses.

Injection site: Subcutaneous administration sites may experience mild, transient reactions (redness, swelling, or discomfort) consistent with any SC injection.

Research Limitations and Gaps

It is important to contextualize ipamorelin's safety profile within the limitations of the existing evidence base:

• •No long-term human RCT data: The majority of ipamorelin-specific human data comes from short-duration pharmacokinetic studies. Long-term randomized controlled trials in humans are absent from the public literature.
• •Most body composition data from animal models: Rodent and porcine studies provide the bulk of preclinical evidence; extrapolation to humans requires cautious interpretation.
• •Lack of FDA approval: Ipamorelin is not FDA-approved for any indication and is classified as a research compound for laboratory use only.
• •Potential for GH feedback effects: Extended GH elevation could theoretically trigger negative feedback at the hypothalamic level, reducing endogenous GHRH output, though this effect appears less pronounced with pulsatile stimulation (as produced by ipamorelin) than with continuous GH elevation.

---

Comparison with Other Growth Hormone Secretagogues

Ipamorelin occupies a specific position in the broader GH secretagogue landscape. Understanding this position requires comparison with the full spectrum of GH-stimulating compounds:

Sermorelin (GHRH 1-29): A GHRH analog acting via GHRH-R rather than GHS-R1a. No direct comparison of selectivity profiles applies (different receptor), but sermorelin complements ipamorelin in combination protocols via the dual-axis synergy described above. Sermorelin has a shorter half-life (~10-12 minutes) than CJC-1295.

CJC-1295 (with/without DAC): Modified GHRH analog with extended half-life. Acts via GHRH-R. The CJC-1295 + ipamorelin combination exploits the complementary GHS-R1a / GHRH-R synergy. See the detailed CJC-1295 vs Ipamorelin comparison.

GHRP-6: GHS-R1a agonist. Equivalent GH-releasing potency to ipamorelin but significantly less selective — elevates cortisol, prolactin, and appetite. Ipamorelin is generally preferred over GHRP-6 for research applications requiring clean GH stimulation.

GHRP-2: GHS-R1a agonist with slightly higher GH-releasing potency than ipamorelin in some assays, but more pronounced cortisol and prolactin elevation than ipamorelin (though less than GHRP-6). GHRP-2 occupies an intermediate position between ipamorelin and GHRP-6 on the selectivity spectrum.

MK-677 (Ibutamoren): Non-peptide, orally bioavailable GHS-R1a agonist. Produces sustained, non-pulsatile GH/IGF-1 elevation due to its long half-life (~24 hours). Significant appetite stimulation and potential fluid retention. Provides a different pharmacodynamic profile (sustained vs. pulsatile) compared to ipamorelin.

For a comprehensive comparison of all five major secretagogues, see the Growth Hormone Secretagogues Compared resource.

---

Research Applications and Tools

Ipamorelin's clean pharmacological profile makes it applicable across several research domains:

Somatotropic axis research: Probing GH pulsatility, somatotroph responsiveness, and IGF-1 dynamics without HPA confounds.

Body composition studies: Investigating GH/IGF-1-mediated changes in fat mass, lean mass, and visceral adipose tissue in animal models of aging, obesity, or GH deficiency.

Bone metabolism research: Studying the role of the GH/IGF-1 axis in bone formation, glucocorticoid-induced osteoporosis models, and growth plate biology.

Sleep architecture studies: Examining how pulsatile GH enhancement affects slow-wave sleep quality, given the established GH-sleep relationship.

Synergy protocols: Quantifying the additive or synergistic GH response when combining GHS-R1a agonists with GHRH-R agonists.

Aging models: Investigating whether restoration of youthful GH pulsatility patterns (which decline with age) affects aging-related outcomes in tissues expressing GH and IGF-1 receptors.

Use the peptide calculator for dose calculations and the stack builder to plan combination research protocols involving ipamorelin.

---

Research Specifications

For peer experience with ipamorelin vendors, see verified supplier reviews for HPLC documentation and purity consistency reports from the research community.

---

Frequently Asked Questions

How does ipamorelin differ from GHRH?

GHRH and ipamorelin both stimulate GH release from the pituitary, but through different receptors (GHRH-R vs. GHS-R1a) and with different mechanisms. GHRH acts only at the pituitary; ipamorelin additionally suppresses somatostatin at the hypothalamic level. Combining them produces synergistic GH release greater than either alone.

Is ipamorelin the same as ghrelin?

No. Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the ghrelin receptor (GHS-R1a), but its structure is entirely different from ghrelin's 28-amino-acid sequence. Ipamorelin was designed to selectively activate GH-releasing pathways while avoiding ghrelin's appetite-stimulating and metabolic effects.

Why is multiple-daily dosing used in research protocols?

Ipamorelin's short 2-hour half-life means each administration produces a single GH pulse that resolves within 3-4 hours. Multiple daily doses are used in research protocols designed to elevate IGF-1 levels substantially over baseline, as each GH pulse contributes to IGF-1 synthesis. Single-dose protocols are preferred for studying acute GH dynamics.

Can ipamorelin be combined with sermorelin?

Yes. The same mechanistic synergy that applies to CJC-1295 + ipamorelin applies to sermorelin + ipamorelin. Sermorelin (GHRH 1-29) activates GHRH-R, complementing ipamorelin's GHS-R1a agonism. The shorter half-life of sermorelin (~10 minutes) means the GH pulse is slightly briefer than with CJC-1295 combinations.

Does ipamorelin cause tolerance or receptor downregulation?

Preclinical studies suggest that pulsatile administration (intermittent dosing) produces less GHS-R1a desensitization than continuous infusion. Research protocols typically include cycle breaks to prevent potential tachyphylaxis, though the clinical significance of downregulation with standard pulse dosing remains under investigation.

---

Research Disclaimer

Ipamorelin is a synthetic peptide compound classified for research use only (RUO). It is not approved by the FDA or other regulatory agencies for use in humans or animals and is not intended for human consumption, therapeutic use, or veterinary application. All information provided on this page is for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Researchers and institutions working with ipamorelin are responsible for compliance with all applicable local, national, and international regulations governing the possession and use of research compounds.

---

Related Research Resources

• •CJC-1295 vs Ipamorelin: Growth Hormone Peptide Research Comparison
• •Growth Hormone Secretagogues Compared
• •Peptide Half-Life Complete Reference Guide
• •Peptide Research Calculator
• •Stack Builder Tool
• •Verified Supplier Reviews — researcher ratings for ipamorelin vendors

---

Further Reading:

• •GHRP-2 (Pralmorelin): The Potent Second-Generation Growth Hormone Secretagogue — Complete Research Profile
• •MK-677 (Ibutamoren): Complete Research Profile — Oral GH Secretagogue, Mechanism, Clinical Data
• •GHRP-6: The Original Growth Hormone Releasing Peptide — Complete Research Profile
• •CJC-1295 DAC: Long-Acting Growth Hormone-Releasing Hormone Analog
• •Reconstitution Calculator
• •Peptide Stack Builder